Foundational Patent Strengthens AI Moat Across Multimodal Data Standardization, Disease Stratification and Gene Mapping
Lunai Bioworks: Fiscal Q2 Earnings Snapshot
SACRAMENTO, Calif. , Feb. 13, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute . Company CEO David Weinstein...
SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ --
AI-driven analysis of Phase 2 survival and progression data aims to identify high-benefit patient subgroups and optimize future registrational trial strategy
Transformer-based biosecurity layer embeds directly into foundation models, using Lunai's proprietary toxicology and in-vivo datasets to detect and prevent creation of previously unknown threat agents...
AI Platform Achieves Key Milestones, Triggering Launch of Alcohol Use Disorder Program
Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61...
AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activity
Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures...